NCT02392312 - Observational Study to Evaluate the Safety and Efficacy of ATG-F on Kidney Transplant Recipients | Biotech Hunter

Enrollment

950

Participants

Timeline

Start Date

January 21, 2015

Primary Completion Date

March 16, 2018

Study Completion Date

March 16, 2018

Conditions

Kidney Transplant Recipients

Interventions

DRUG

ATF-Fresenius S

intravenous

Trial Locations (25)

Site: CN00004, Baotou

Site: CN00011, Beijing

Site: CN00012, Beijing

Site: CN00013, Beijing

Site: CN00016, Changchun

Site: CN00002, Chengdu

Site: CN00003, Chongqing

Site: CN00018, Fuzhou

Site: CN00023, Guangzhou

Site: CN00021, Haikou

Site: CN00022, Haikou

Site: CN00019, Hangzhou

Site: CN00020, Hangzhou

Site: CN00006, Jinan

Site: CN00017, Jinan

Site: CN00028, Kunming

Site: CN00030, Nanchang

Site: CN00015, Qingdao

Site: CN00010, Shiyan

Site: CN00014, Taiyuan

Site: CN00005, Tianjin

Site: CN00031, Ürümqi

Site: CN00001, Xi'an

Site: CN00033, Yantai

Site: CN00007, Zhengzhou

All Listed Sponsors

lead

Astellas Pharma China, Inc.

INDUSTRY